RT info:eu-repo/semantics/article
T1 Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment
A1 Jurišić Dukovski, Bisera
A1 Juretić, Marina
A1 Bračko, Danka
A1 Randjelović, Danijela
A1 Savić, Snežana
A1 Crespo Moral, Mario
A1 Diebold Luque, María Yolanda
A1 Filipović Grčić, Jelena
A1 Pepić, Ivan
A1 Lovrić, Jasmina
K1 Oftalmología
K1 Dry eye disease
K1 Nanoemulsion
K1 NSAID
K1 Enfermedad del ojo seco
K1 Nanoemulsión
K1 AINE
K1 3201.09 Oftalmología
AB Inflammation plays a key role in dry eye disease (DED) affecting millions of people worldwide. Non-steroidal anti-inflammatory drugs (NSAIDs) can be used topically to act on the inflammatory component of DED, but their limited aqueous solubility raises formulation issues. The aim of this study was development and optimization of functional cationic nanoemulsions (NEs) for DED treatment, as a formulation approach to circumvent solubility problems, prolong drug residence at the ocular surface and stabilize the tear film. Ibuprofen was employed as the model NSAID, chitosan as the cationic agent, and lecithin as the anionic surfactant enabling chitosan incorporation. Moreover, lecithin is a mixture of phospholipids including phosphatidylcholine and phosphatidylethanolamine, two constituents of the natural tear film important for its stability. NEs were characterized in terms of droplet size, polydispersity index, zeta-potential, pH, viscosity, osmolarity, surface tension, entrapment efficiency, stability, sterilizability and in vitro release. NEs mucoadhesive properties were tested rheologically after mixing with mucin dispersion. Biocompatibility was assessed employing 3D HCE-T cell-based model and ex vivo model using porcine corneas. The results of our study pointed out the NE formulation with 0.05% (w/w) chitosan as the lead formulation with physicochemical properties adequate for ophthalmic application, mucoadhesive character and excellent biocompatibility.
PB Elsevier
SN 0378-5173
YR 2020
FD 2020
LK https://uvadoc.uva.es/handle/10324/64984
UL https://uvadoc.uva.es/handle/10324/64984
LA eng
NO International Journal of Pharmaceutics, 2020, vol. 576, 118979
NO Producción Científica
DS UVaDOC
RD 17-jul-2024